Compare Infosys Limited (INFY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Infosys Limited trades at $11.76 (market cap $46.25B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Infosys Limited is far larger — about 47.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Infosys Limited pays a 4.56% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| INFY | MRVI | |
|---|---|---|
Market Cap | $46.25B | $977.37M |
Volume | 14,209,421 | 2,742,564 |
Sector | Technology | Health |
52-Week High | $20.22 | $9.00 |
52-Week Low | $10.49 | $2.83 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $44.00B | $1.08B |
Dividend Yield | 4.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal and strong profitability metrics including a 16.37% net margin and 32.12% ROE. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, signaling growth initiatives.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering modest upside. Risks include potential earnings volatility and competitive pressures in IT services. Analyst sentiment is mixed with 35% buy ratings, but strong cash flow and institutional interest support a stable investment case amid sector headwinds.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
